ID   HL60/AR
AC   CVCL_WI27
SY   HAR
DR   cancercelllines; CVCL_WI27
DR   Wikidata; Q94211961
RX   PubMed=24368162;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Caution: Not to be confused with HL-60/AR (Cellosaurus=CVCL_WR44) which is an anthracycline resistant subline of HL-60.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0002 ! HL-60
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 05-10-23; Version: 11
//
RX   PubMed=24368162; DOI=10.1016/j.exphem.2013.12.004;
RA   Sripayap P., Nagai T., Uesawa M., Kobayashi H., Tsukahara T.,
RA   Ohmine K., Muroi K., Ozawa K.;
RT   "Mechanisms of resistance to azacitidine in human leukemia cell
RT   lines.";
RL   Exp. Hematol. 42:294-306(2014).
//